Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review.
Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review.
复制标题
DOI：
10.1186/s12885-016-2422-y
复制
发表时间：
2016-07-07
期刊：
影响因子：
3.8
通讯作者：
Baba H
中科院分区：
文献类型：
--
作者：
Harada K;Baba Y;Shigaki H;Ishimoto T;Miyake K;Kosumi K;Tokunaga R;Izumi D;Ohuchi M;Nakamura K;Kiyozumi Y;Kurashige J;Iwatsuki M;Miyamoto Y;Sakamoto Y;Yoshida N;Watanabe M;Baba H
已在几种类型的癌中观察到激活PI 3 K/AKT信号传导途径的磷脂酰肌醇-4，5-二磷酸3-激酶催化亚基α（PIK 3CA）突变，并与患者预后相关。然而，PIK 3CA突变在胃癌中的意义仍不清楚。这项回顾性研究调查了PIK 3CA突变与胃癌患者临床结局之间的关系。此外，我们回顾了胃癌中PIK 3CA突变的发生率以及PIK 3CA突变与人类癌症预后之间的关系。该研究包括2001年1月至2010年8月期间在日本熊本大学医院接受手术切除的208名胃癌患者。通过焦磷酸测序测定定量PIK 3CA外显子9和20中的突变。在208例患者中的25例（12%）中检测到PIK 3CA突变。10例患者有c.1634A > G（p.E545G），10例有c.1624G > A（p.E542K），13例有c.1633G > A（p.E545K），9例有c.3139C > T（p.H1047R），1例有c.3140A > G（p.H1047Y）突变。PIK 3CA突变与任何临床、流行病学或病理学特征均无显著相关性。Kaplan-Meier分析显示，在具有和不具有PIK 3CA突变的患者之间，无病生存期（log rank P = 0.84）和总生存期（log rank P = 0.74）没有显著差异。PIK 3CA突变与胃癌患者的预后无关，这为两者之间缺乏关系提供了额外的证据。
Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutations that activate the PI3K/AKT signaling pathway have been observed in several types of carcinoma and have been associated with patient prognosis. However, the significance of PIK3CA mutations in gastric cancer remains unclear. This retrospective study investigated the relationship between PIK3CA mutations and clinical outcomes in patients with gastric cancer. Additionally, we reviewed the rate of PIK3CA mutations in gastric cancer and the association between PIK3CA mutations and prognosis in human cancers. The study included 208 patients with gastric cancer who underwent surgical resection at Kumamoto University Hospital, Japan, between January 2001 and August 2010. Mutations in PIK3CA exons 9 and 20 were quantified by pyrosequencing assays. PIK3CA mutations were detected in 25 (12 %) of the 208 patients. Ten patients had c.1634A > G (p.E545G), 10 had c.1624G > A (p.E542K), 13 had c.1633G > A (p.E545K), nine had c.3139C > T (p.H1047R), and 1 had c.3140A > G (p.H1047Y) mutations. PIK3CA mutations were not significantly associated with any clinical, epidemiologic, or pathologic characteristic. Kaplan–Meier analysis showed no significant differences in disease-free survival (log rank P = 0.84) and overall survival (log rank P = 0.74) between patients with and without PIK3CA mutations. Mutations in PIK3CA did not correlate with prognosis in patients with gastric cancer, providing additional evidence for the lack of relationship between the two.